Skip to main content
CTOS 2024 Main banner
Final Program


Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Session 15: Desmoid Fibromatosis and TGCT

Saturday, November 16, 2024
3:30 PM – 4:30 PM PST
Location: Harbor Ballroom

Presentations:

  • 3:30 PM – 4:30 PM PST
    EFFICACY OF NIROGACESTAT IN PATIENTS WITH DESMOID TUMORS AND POOR PROGNOSTIC FACTORS: PATIENT-REPORTED OUTCOMES, PROGRESSION-FREE SURVIVAL, AND OBJECTIVE RESPONSE RATE IN THE PHASE 3 DEFI TRIAL

    Author: Bruno Vincenzi, MD, PhD – Policlinico Universitario Campus Bio-Medico

    Co-Author: Nam Quoc Bui, MD – Division of Oncology, Department of Medicine, Stanford University

    Co-Author: Palma Dileo, MD (she/her/hers) – University College London Hospitals NHS Foundation Trust

    Co-Author: Noah Federman, MD – UCLA David Geffen School of Medicine

    Co-Author: Richard F. Riedel, MD – Duke Cancer Institute

    Co-Author: Brian A. Van Tine, MD, PhD – Washington University in St. Louis

    Co-Author: Shengfan Zhou, MS – SpringWorks Therapeutics, Inc.

    Co-Author: Timothy Bell, MHA – SpringWorks Therapeutics, Inc.

    Co-Author: Yucheng Chu, MS – Sumptuous Data Sciences

    Co-Author: Allison Lim, PharmD – SpringWorks Therapeutics, Inc.

    Co-Author: Ana B. Oton, MD – SpringWorks Therapeutics, Inc.

    Co-Author: Bernd Kasper, MD, PhD (he/him/his) – University of Heidelberg, Mannheim University Medical Center, Mannheim Cancer Center (MCC)

  • 3:30 PM – 4:30 PM PST
    NIROGACESTAT TREATMENT IN ADULT PATIENTS WITH DESMOID TUMORS: LONG-TERM EFFICACY AND SAFETY FROM THE PHASE 3 DEFI TRIAL

    Author: Ravin Ratan, MD, MEd – University of Texas, MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Division of Cancer Medicine

    Co-Author: Bernd Kasper, MD, PhD (he/him/his) – University of Heidelberg, Mannheim University Medical Center, Mannheim Cancer Center (MCC)

    Co-Author: Patrick Schöffski, Prof Dr – Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven

    Co-Author: Winette van der Graaf, MD, PhD – Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center

    Co-Author: Noah Federman, MD – Departments of Pediatrics and Orthopaedic Surgery, David Geffen School of Medicine, University of California Los Angeles

    Co-Author: Nam Quoc Bui, MD – Division of Oncology, Department of Medicine, Stanford University

    Co-Author: Allison Lim, PharmD – SpringWorks Therapeutics, Inc.

    Co-Author: Ana B. Oton, MD – SpringWorks Therapeutics, Inc.

    Co-Author: Yucheng Chu, MS – Sumptuous Data Sciences

    Co-Author: Brad Tumminello, PharmD – SpringWorks Therapeutics, Inc.

    Co-Author: Mrinal Gounder, MD – Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College

    Co-Author: Shengfan Zhou, MS – SpringWorks Therapeutics, Inc.

  • 3:30 PM – 4:30 PM PST
    IMMUNOLOGICAL PROFILING OF PATIENTS WITH DESMOID FIBROMATOSIS UNDER ACTIVE SURVEILLANCE: RESULTS OF A LONGITUDINAL MONITORING IN A PROSPECTIVE TRIAL

    Co-Author: Laura Bergamaschi, MSc – Fondazione IRCCS Istituto Nazionale dei Tumori

    Co-Author: Stefano P. Percio, PhD – Fondazione IRCCS Istituto Nazionale dei Tumori

    Co-Author: Zorza Marta, PhD – Fondazione IRCCS Istituto Nazionale dei Tumori

    Co-Author: Rini Francesca, n/a – Fondazione IRCCS Istituto Nazionale dei Tumori

    Co-Author: Elisabetta Vergani, PhD (she/her/hers) – Fondazione IRCCS Istituto Nazionale dei Tumori

    Co-Author: Banfi Cristina, n/a – Fondazione IRCCS Istituto Nazionale dei Tumori

    Co-Author: rivoltini Licia, PhD – Fondazione IRCCS Istituto Nazionale dei Tumori

    Co-Author: Alessandro Gronchi, MD, FSSO (he/him/his) – Fondazione IRCCS Istituto Nazionale dei Tumori

    Presenter: Sandro Pasquali, MD, PhD – Fondazione IRCCS Istituto Nazionale dei Tumori

    Co-Author: Viviana Vallacchi, PhD (she/her/hers) – Fondazione IRCCS Istituto Nazionale dei Tumori

    Author: Chiara Colombo, MD – Fondazione IRCCS Istituto Nazionale dei Tumori

  • 3:30 PM – 4:30 PM PST
    EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES OF VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR: RESULTS FROM THE MOTION PHASE 3 TRIAL

    Author: Nicholas M. Bernthal, MD – University of California Los Angeles

    Co-Author: William D. Tap, MD – Department of Medicine, Memorial Sloan Kettering Cancer Center Department of Medicine, Weill Cornell Medical College

    Co-Author: Vivek A. Bhadri, MD, PhD – Chris O’Brien Lifehouse

    Co-Author: Silvia Stacchiotti, MD – Fondazione IRCCS Istituto Nazionale dei Tumori

    Co-Author: Sebastian Bauer, MD (he/him/his) – Sarcoma Center, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, and German Cancer Consortium (DKTK), Partner Site University Hospital Essen

    Co-Author: Andrew J. Wagner, MD, PhD – Dana-Farber Cancer Institute

    Co-Author: Michiel AJ van de Sande, Professor (he/him/his) – Princes Maxima Center for pediatric oncology and LUMC leiden

    Co-Author: Antonio López Pousa, MD – Hospital de la Santa Creu i Sant Pau

    Co-Author: Albiruni Abdul Razak, MB BCh, BAO, LRCP & SI – Toronto Sarcoma Program, Princess Margaret Cancer Center

    Co-Author: Antoine Italiano, MD, PhD – Institut Bergonié

    Co-Author: Mahbubl Ahmed, MSc, MBBS, PhD – University College London Hospitals NHS Foundation Trust

    Co-Author: Axel Le Cesne, MD – Gustave Roussy

    Co-Author: Christopher Tait, PhD – Deciphera Pharmaceuticals, LLC

    Co-Author: Amanda Saunders, DO – Deciphera Pharmaceuticals, LLC

    Co-Author: Brooke Harrow, PhD – Deciphera Pharmaceuticals, LLC

    Co-Author: Maitreyi G. Sharma, MD – Deciphera Pharmaceuticals, LLC

    Co-Author: Rodrigo Ruiz-Soto, MD – Deciphera Pharmaceuticals, LLC

    Co-Author: Matthew L. Sherman, MD – Deciphera Pharmaceuticals, LLC

    Co-Author: Jean-Yves Blay, MD, PhD – Centre Léon Bérard

    Co-Author: Hans Gelderblom, MD, PhD – Leiden University Medical Center

  • 3:30 PM – 4:30 PM PST
    SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY

    Author: Andrew J. Wagner, MD, PhD – Dana-Farber Cancer Institute

    Co-Author: Gina D’Amato, MD – Sylvester Comprehensive Cancer Center, University of Miami

    Co-Author: Kristen N. Ganjoo, MD – Stanford Comprehensive Cancer Center

    Co-Author: Silvia Stacchiotti, MD – Fondazione IRCCS Istituto Nazionale dei Tumori

    Co-Author: Hans Gelderblom, MD, PhD – Leiden University Medical Center

    Co-Author: Christopher W. Ryan, MD – OHSU Knight Cancer Institute

    Co-Author: Emanuela Palmerini, MD, PhD – IRCCS Istituto Ortopedico Rizzoli

    Co-Author: Vinod Ravi, MD, MBA – The University of Texas MD Anderson Cancer Center

    Co-Author: Ramy Saleh, MD – McGill University Health Centre Research Institute

    Co-Author: Axel Le Cesne, MD – Gustave Roussy

    Co-Author: Nicholas M. Bernthal, MD – University of California Los Angeles

    Co-Author: Michiel AJ van de Sande, Professor (he/him/his) – Princes Maxima Center for pediatric oncology and LUMC leiden

    Co-Author: Supraja Narasimhan, PhD (she/her/hers) – Deciphera Pharmaceuticals, A member of ONO Pharma

    Co-Author: Brooke Harrow, PhD – Deciphera Pharmaceuticals, LLC

    Co-Author: Amanda Saunders, DO – Deciphera Pharmaceuticals, LLC

    Co-Author: Rodrigo Ruiz-Soto, MD – Deciphera Pharmaceuticals, LLC

    Co-Author: Matthew L. Sherman, MD – Deciphera Pharmaceuticals, LLC

    Co-Author: William D. Tap, MD – Department of Medicine, Memorial Sloan Kettering Cancer Center Department of Medicine, Weill Cornell Medical College

  • 3:30 PM – 4:30 PM PST
    PEXIDARTINIB USE IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR: AN ANALYSIS OF THE PHASE III RANDOMIZED ENLIVEN CLINICAL TRIAL ACCORDING TO SURGICAL HISTORY

    Author: John H. Healey, MD – Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College

    Co-Author: Andrew J. Wagner, MD, PhD – Dana-Farber Cancer Institute

    Co-Author: Silvia Stacchiotti, MD – Fondazione IRCCS Istituto Nazionale dei Tumori

    Co-Author: Meng Qian, PhD – Daiichi Sankyo, Inc.

    Co-Author: Kristen Tecson, PhD – Daiichi Sankyo, Inc.

    Co-Author: Margaret Wooddell, PhD, MBA – Daiichi Sankyo, Inc.

    Presenter: William D. Tap, MD – Department of Medicine, Memorial Sloan Kettering Cancer Center Department of Medicine, Weill Cornell Medical College